Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impella 5.5 in ADHF-CS
NCT05064202Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in heart failure (HF) and cardiogenic shock (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite of all-cause mortality, renal replacement therapy and rehospitalization or urgent visit for heart failure at 90 days. Planned start Oct 2023; status: not yet recruiting.
02
Conditions
heart failure (HF)cardiogenic shock
Beyond the preview
Go deeper on NCT05064202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064202.